Abstract

Recently, we identified ELL2 as a susceptibility gene for multiple myeloma (MM). To understand its mechanism of action, we performed expression quantitative trait locus analysis in CD138+ plasma cells from 1630 MM patients from four populations. We show that the MM risk allele lowers ELL2 expression in these cells (Pcombined = 2.5 × 10−27; βcombined = −0.24 SD), but not in peripheral blood or other tissues. Consistent with this, several variants representing the MM risk allele map to regulatory genomic regions, and three yield reduced transcriptional activity in plasmocytoma cell lines. One of these (rs3777189-C) co-locates with the best-supported lead variants for ELL2 expression and MM risk, and reduces binding of MAFF/G/K family transcription factors. Moreover, further analysis reveals that the MM risk allele associates with upregulation of gene sets related to ribosome biogenesis, and knockout/knockdown and rescue experiments in plasmocytoma cell lines support a cause–effect relationship. Our results provide mechanistic insight into MM predisposition.

Details

Title
The multiple myeloma risk allele at 5q15 lowers ELL2 expression and increases ribosomal gene expression
Author
Ali, Mina 1 ; Ajore, Ram 1 ; Wihlborg, Anna-Karin 1 ; Niroula, Abhishek 1   VIAFID ORCID Logo  ; Swaminathan, Bhairavi 1 ; Johnsson, Ellinor 1 ; Stephens, Owen W 2 ; Morgan, Gareth 2 ; Meissner, Tobias 3 ; Turesson, Ingemar 1 ; Goldschmidt, Hartmut 4 ; Ulf-Henrik Mellqvist 5 ; Gullberg, Urban 1 ; Hansson, Markus 6   VIAFID ORCID Logo  ; Hemminki, Kari 7 ; Nahi, Hareth 8 ; Waage, Anders 9 ; Weinhold, Niels 2 ; Nilsson, Björn 10 

 Department of Laboratory Medicine, Hematology and Transfusion Medicine, Lund, Sweden 
 Myeloma Institute for Research and Therapy, University of Arkansas for Medical Sciences, Little Rock, AR, USA 
 Department of Molecular and Experimental Medicine, Avera Cancer Institute, Sioux Falls, SD, USA 
 Department of Internal Medicine V, University of Heidelberg, Heidelberg, Germany; National Center for Tumor Diseases, Heidelberg, Germany 
 Section of Hematology, South Elvsborg Hospital, Borås, Sweden 
 Department of Laboratory Medicine, Hematology and Transfusion Medicine, Lund, Sweden; Hematology Clinic, Skåne University Hospital, Lund, Sweden 
 German Cancer Research Center, Heidelberg, Germany; Center for Primary Health Care Research, Lund University, Malmö, Sweden 
 Center for Hematology and Regenerative Medicine, Karolinska Institutet, Stockholm, Sweden 
 Department of Cancer Research and Molecular Medicine, Norwegian University of Science and Technology, Trondheim, Norway 
10  Department of Laboratory Medicine, Hematology and Transfusion Medicine, Lund, Sweden; Broad Institute, Cambridge, MA, USA 
Pages
1-9
Publication year
2018
Publication date
Apr 2018
Publisher
Nature Publishing Group
e-ISSN
20411723
Source type
Scholarly Journal
Language of publication
English
ProQuest document ID
2030841232
Copyright
© 2018. This work is published under http://creativecommons.org/licenses/by/4.0/ (the “License”). Notwithstanding the ProQuest Terms and Conditions, you may use this content in accordance with the terms of the License.